Riptin contains Amitriptyline + Chlordiazepoxide. Riptin uses:
Depression with Anxiety, agitation or tension.
Brand Name: | Riptin |
Generic: | Amitriptyline + Chlordiazepoxide |
Weight: | 10.0 Mg |
Type: | Tablet |
Therapeutic Class: | Combined anxiolytics & anti-depressant drugs |
Manufacturer: | NEURO LIFE SCIENCE |
Price: | 15.3 |
Last Updated: | 2020-11-21 18:15:00 |
Riptin contains Amitriptyline + Chlordiazepoxide 10.0 Mg. Riptin doses
1 tablet (5 mg chlordiazepoxide and 12.5 mg amitriptyline) three to four times daily; may increase to 6 tablets if necessary
Drowsiness, Dry mouth, Constipation, Blurred vision, Dizziness, Bloating, Vivid dreams, Impotence, Tremor, Confusion, Nasal congestion, Edema, Syncope, Ataxia, EEG abnormalities, Menstrual irregularities, Blood dyscrasias (agranulocytosis), Hepatic dysfunction (jaundice).
Chlordiazepoxide: Chlordiazepoxide enhances activity of the inhibitory transmitter GABA in different parts of CNS by increasing neuronal-membrane permeability to chloride ions resulting to hyperpolarisation and stabilisation. It has some muscle relaxant and anticonvulsant activity.
Amitriptyline: Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (age <24 yr) taking antidepressants for major depressive disorders and other psychiatric illnesses.
Caution in BPH, urinary/GI retention, increased IOP, thyroid dysfunction, open-angle glaucoma, seizure disorders, brain tumor, respiratory impairment, respiratory disease. Risk of anticholinergic side-effects. May cause orthostatic hypotension. Paradoxical reactions including hyperactive or aggressive behavior reported.
Both agents may cause sedation and impair ability to perform tasks requiring mental alertness. Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies; monitor during the initial 1 -2 months of therapy and dosage adjustments.
Not approved for treatment of dementia-related psychosis.
Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Lactation: Excretion in milk unknown; not recommended
Hypersensitivity. Severe cardiovascular disorders, Angle clossure glaucoma, Within 14 days of MAOIs, Any drugs or conditions that prolong QT interval, Acute recovery post-MI.
Riptin Tablet price in India 15.3